Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prosonix Extends Series B Financing, Plans Generic Fluticasone Filing

This article was originally published in The Pink Sheet Daily

Executive Summary

Prosonix receives an extra $9 million for its Series B round as it changes business strategy from contract research to the development of generic respiratory products, based on a novel particle-engineering technology for inhaled powders.

You may also be interested in...

Mylan, Prosonix Use In Vitro Data To File Generic Fluticasone Inhaler In EU

Marketing submissions for generic inhaled respiratory products based on in vitro data alone may be less expensive and a quicker route to market than other EU regulatory processes for inhaled generics.

Deal Watch: Nanotech Formulations Of Doxorubicin Highlight Recent Deal-Making

France’s BioAlliance adds to its oncology portfolio through an all-equity merger with Topotarget; NanoSmart and NanoValent team up on an ovarian cancer program; Mylan licenses two respiratory therapies from Prosonix; and Actavis adds to its specialty generics portfolio with products from Akorn.

Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off

Plus news on recent financing activity by TVM Capital, Royalty Pharma, Prosonix and Sangart.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts